SCHEMBL2863040

SCHEMBL2863040

COc1ccc(Cn2c(=O)c3c(N)n(-c4ccccc4C)nc3c3cc(OC)c(OC(C)C)cc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
MAPK1 P28482 2/20 0.43
GAA P10253 1/20 0.43
NPC1 O15118 1/20 0.41
KDM4E B2RXH2 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
THRB P10828 1/20 0.38
PDE1A P54750 1/20 0.38
PDE1B Q01064 1/20 0.38
PDE1C Q14123 1/20 0.38
RXFP1 Q9HBX9 1/20 0.37
ALDH1A1 P00352 3/20 0.37
LMNA P02545 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
IDE P14735 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2864991 0.95 NPC1 (0.44) MAPTKMT2AMEN1GAANPC1
SCHEMBL2866734 0.93 MAPT (0.42) MAPTKMT2AMEN1MAPK1GAA
SCHEMBL2871290 0.88 MAPT (0.42) MAPTKMT2AMEN1MAPK1GAA
SCHEMBL2871608 0.87 KDM4E (0.42) MAPTKMT2AMEN1NPC1KDM4E
SCHEMBL2861196 0.86 MAPK1 (0.42) MAPTKMT2AMEN1MAPK1GAA
SCHEMBL2859868 0.84 KDM4E (0.40) MAPTKDM4ETHRBPDE1APDE1B
SCHEMBL2861590 0.83 NPC1 (0.44) MAPK1GAANPC1KDM4ESMN1; SMN2
SCHEMBL2857641 0.83 PDE1B (0.38) MAPTKMT2AMEN1MAPK1GAA
SCHEMBL2861122 0.83 PDE1A (0.39) MAPTKMT2AMEN1MAPK1GAA
SCHEMBL2858941 0.83 GAA (0.38) MAPTKMT2AMEN1MAPK1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 MAPT 4583/4885KMT2A 1037/4885MEN1 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.